Cystic Fibrosis: Successes, Opportunities And Challenges

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.

IV1702_CysticFibrosis_Feature_1200

Vertex Pharmaceuticals Inc.has quickly established itself as the one to beat across the cystic fibrosis market, and the company is expecting critical data readouts for some of its pipeline products this year. Still, the early-stage pipeline for this rare disease indication is plentiful, including activity from Vertex's former hepatitis C rival, AbbVie Inc.

In parallel to new therapies coming to the fore only a few years after the launch of Vertex's standard-of-care-altering Kalydeco...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Growth

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By 

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.

Dealmaking Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Financing Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

More from In Vivo

Dealmaking Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By 

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By 

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.